News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oncothyreon Inc. (ONTY) to Present at Wedbush Securities Life Sciences Management Access Conference


8/6/2013 7:19:44 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE, Aug. 6, 2013 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Julie Eastland, Chief Financial Officer and Vice President, Corporate Development, will present at the Wedbush Securities Life Sciences Management Access Conference in New York on Tuesday, Aug. 13, 2013 at 1:55 p.m. Eastern.

A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.

SEATTLE, Aug. 6, 2013 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Julie Eastland, Chief Financial Officer and Vice President, Corporate Development, will present at the Wedbush Securities Life Sciences Management Access Conference in New York on Tuesday, Aug. 13, 2013 at 1:55 p.m. Eastern.

A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES